BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver ...
Phase Ib, open-label study of add on therapy with CK0804 in participants with myelofibrosis, with suboptimal response to ruxolitinib. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback